We conducted the AIDA trial comparing the Absorb™ bioresorbable vascular scaffold (BVS; Abbott Vascular, Santa Clara, CA, USA) with the XIENCE everolimus-eluting stent (EES; Abbott Vascular) in daily practice to assess the complete safety and efficacy of the Absorb throughout the scaffold bioresorption period. Preclinical studies have shown that scaffold bioresorption takes 36 months1. Clinical studies have demonstrated that this period of scaffold bioresorption is associated with higher rates of device thrombosis2. Therefore, we herein report the complete three-year clinical outcomes of the Absorb in comparison with the XIENCE.
The study design, study population ...
Sign in to read and download the full articleForgot your password?
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com